<DOC>
	<DOCNO>NCT01066754</DOCNO>
	<brief_summary>Randomized , 2-Way Crossover , Bioequivalence Study Fexofenadine Hydrochloride 180 mg Tablets Dr.Reddy 's Laboratories Limited , Allegra® 180 mg Tablets , Aventis Administered 1 x 180 mg Tablet Healthy Subjects Fasting Conditions</brief_summary>
	<brief_title>Bioequivalence Study Dr.Reddy 's Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions</brief_title>
	<detailed_description>The objective study compare rate extent absorption fexofenadine hydrochloride 180 mg tablet ( test ) versus Allegra® ( reference ) administer 1 x 180 mg tablet fast condition . Single oral dose ( 1 x 180 mg ) period washout least 7 day dos .</detailed_description>
	<mesh_term>Fexofenadine</mesh_term>
	<mesh_term>Terfenadine</mesh_term>
	<criteria>Subjects enrol study member community large . The recruitment advertisement may do use different medium ( e.g . radio , newspaper , Anapharm Inc . Web site , Anapharm Inc. volunteer ' data base ) . Subjects must meet follow criterion order include study : Subjects females and/or male , smoker nonsmoker , 18 year age old . Female subject postmenopausal surgically sterilize . Postmenopausal status define absence menses past 12 month hysterectomy bilateral oophorectomy least 6 month ago . Sterile status define hysterectomy , bilateral oophorectomy tubal ligation least 6 month ago . Subjects follow applies exclude study : Clinically significant illness within 4 week administration study medication . Clinically significant surgery within 4 week prior administration study medication . Any clinically significant abnormality find medical screening . Any reason , opinion medical sub investigator , would prevent subject participate study . Abnormal laboratory test judge clinically significant . Positive urine drug screen screen . Positive test hepatitis B , hepatitis C HN screen . ECG abnormality ( clinically significant ) vital sign abnormality ( systolic blood pressure low 90 140 mmHg , diastolic blood pressure low 50 90 ; heart rate le 50 bpm 100 bpm ) screening . Subjects BMl ≥ 30.0 . History significant alcohol abuse within six month screen visit indication regular use two unit alcohol per day ( 1 Unit = 150 mL wine 360 mL beer 45 mL alcohol 40 % ) . History drug abuse use illegal drug : use soft drug ( marijuana ) within 3 month screen visit hard drug ( cocaine , phencyclidine ( PCP ) crack ) within 1 year screen visit . Any food allergy , intolerance , restriction special diet , opinion medical Sub investigator , contraindicate subject 's participation study . History allergic reaction fexofenadine hydrochloride ingredient . History allergic reaction heparin . Use drug know induce inhibit hepatic drug metabolism ( examples inducer : barbiturate , carbamazepine , phenytoin , glucocorticoid , rifampin/rifabutin ; examples inhibitor : antidepressant , cimetidine , diltiazem , erythromycin , ketoconazole , MAO inhibitor , neuroleptic , verapamil , quinidine ) , use investigational drug participation investigational study within 30 day prior administration study medication . Use prescription medication within 14 day prior administration study medication overthecounter product ( include natural product , vitamin , garlic supplement ) within 7 day prior administration study medication , except topical product without systemic absorption . Subjects depot injection implant drug 3 month prior administration study medication . Donation plasma ( 500 mL ) within 7 day . Donation loss whole blood prior administration study medication follow : less 300 mL whole blood within 30 day 300 mL 500 mL whole blood within 45 day 500 mL whole blood within 56 day . Smoking 25 cigarette per day . Additional exclusion criterion female : Breastfeeding subject . Positive urine pregnancy test screening ( performed female ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>